GenesisTissue - Lightning Pitch

Why It Matters

By replacing synthetic implants with a degradable, patient‑derived scaffold, Genesis Tissue could dramatically lower complication rates and set a new standard for breast reconstruction, benefiting surgeons and survivors alike.

Key Takeaways

• Genesis Tissue offers 3D‑bioprinted scaffold for breast reconstruction.
• Scaffold supports fat grafting, degrades, leaving only patient’s tissue.
• Product is soft, feels like natural breast tissue, radio‑opaque.
• Personalized designs enable tailored reconstruction for individual patients.
• Aims to replace complications of saline and silicone implants.

Summary

Genesis Tissue’s Lightning Pitch introduced a novel regenerative breast tissue solution—a 3D‑bioprinted scaffold designed to replace traditional saline and silicone implants. CEO Katie Wymer highlighted the growing demand for better reconstruction options as breast‑cancer survival rates improve, positioning the technology as a response to persistent implant complications.

The scaffold provides immediate mechanical support, allowing autologous fat grafts to engraft securely. Over time, the biodegradable matrix dissolves, leaving only the patient’s own tissue. It is radio‑opaque for imaging, mimics the softness of natural breast tissue, and can be customized to each patient’s anatomy, promising a more personalized surgical outcome.

Wymer emphasized, “Genesis Tissue is not just improving reconstruction, we’re redefining it,” underscoring the company’s ambition to shift the standard of care. She delivered the pitch while her son performed his first solo flight, a personal anecdote that underscored the urgency and emotional stakes of breast‑cancer recovery.

If adopted widely, the technology could reduce revision surgeries, lower infection rates, and create a new market segment for bio‑engineered implants, potentially reshaping the breast‑reconstruction industry and offering patients a more natural, lasting result.